Seen as the next step in minimally invasive spine surgery, OZOP’s technology would combine an endoscope with an implant that can be placed inside the human body using a small incision and a tube to deliver the balloon which would then expand in the interbody space. Through the incision, the endoscope enters and prepares the interbody space. Then the balloon is placed which expands and takes the shape of the final implant. A settable polymer is injected in a flowable form into the balloon. The polymer then gradually hardens in place. “With our technology, the future of spine fusion surgeries would be through a puncture and then inserting an expandable interbody device,” says Michael Chermak, CEO at OZOP.
OZOP is also developing a surgical 3D endoscope that would improve the visualization of the surgical field during endoscopic procedures. The technology produces 3D images of the field at 4k video quality which the surgeons see in real time. The video has better depth perception and shows anatomic features in great detail to improve overall surgical results. Moreover, OZOP is also coming up with their proprietary molecular endoscope technology which uses multiple light sources and captures light waves outside the visible spectrum. These images are then filtered in real-time to enhance the image seen by the surgeon to help them identify vascular structures that are hard to differentiate from the muscular anatomy in the surgical field.
In addition to these upcoming technological products, OZOP also manufactures many traditional spine surgery products that cover more than 80 percent of all spine fusion procedures performed. These products come along with a complementary line of instrumentation that is manufactured to meet industry standards.
One of the critical elements behind OZOP’s future-native thinking has been a team with decades of experience working with healthcare-related ventures. Apart from the core team, they also work with experienced contract engineers and regulatory experts in addition to surgeons with a history of developing, training, and commercializing numerous spine products.
With these innovative products in the pipeline, Chermak stresses that OZOP’s focus is on the delivery of all interbody devices through an endoscope. “After we develop our first endoscopic implant, we look forward to using the technology to develop other implants within the spine space,” concludes McLeer.
OZOP Surgical [OTCQB:OZSC] News
Ozop Surgical Corp. Announces Successful Up-Listing Approval to OTCQB Marketplace
West Palm Beach, Fla. - Ozop Surgical Corp. (OTCQB: OZSC), announces that effective today it now trades on the OTCQB Venture Market for early stage and developing U.S. and international companies. Click here to see interview with Michael Chermak, CEO of Ozop, https://www.youtube.com/embed/-BDs9I_I8Ac. To qualify for the listing, companies must be current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com/stock/OZSC/quote.
“Our Company is committed to the high level of financial and corporate disclosure that is required for this listing category, which demonstrates our continued commitment to our shareholders. We believe that trading on the OTCQB and being DTC eligible will raise the visibility of the Company, enhance trading liquidity, and broaden our shareholder base as we move forward with market acceptance and penetration of our products and services,” stated Michael Chermak, CEO of Ozop.
“These milestones open the door to institutional investors and market makers who were not previously able to buy and sell shares of our Company. Now they may execute on unsolicited orders and also make recommendations to clients as they so choose. Meeting the increased compliance and information requirements of OTCQB provides our investors greater confidence in the information disclosed by the Company and ensures our commitment to accountability and transparency.”
In 2014, OTC Markets Group introduced standards and eligibility requirements for OTCQB with the goal of making it a better venture marketplace. To be eligible, companies must be current in their reporting to a U.S. or foreign regulator, pass a minimum bid price test of one penny ($0.01), maintain a public float above 5% of total shares issued and outstanding and a market value of public float of at least $2 million and undergo an annual verification and management certification process providing additional information about the company’s insiders, advisors and share count, among other things. Companies that are approved to trade on OTCQB receive access to additional premium services to help them build visibility and improve transparency for investors.